DA-EPOCH-R No More Effective Than R-CODOX-M/R-IVAC in Burkitt Lymphoma
The 2 regimens produced similar efficacy outcomes, but adverse events were more common in the R-CODOX-M/R-IVAC arm.
Diagnosis & Disease Information
Academic BCMA CAR T-Cell Therapy “Promising” in Rel/Ref Multiple Myeloma
The overall response rate was 100%, and the 18-month progression-free survival rate was 53%.
Quizartinib Improves Overall Survival in FLT3-ITD+ Acute Myeloid Leukemia
Results from the phase 3 QuANTUM-First trial have the potential to change standard care for adults with newly diagnosed FLT3-ITD+ acute myeloid leukemia, according to the lead study author.
Study: Nearly One-Third of Children With Hematologic Cancers Develop Cardiotoxicity
All patients with cardiotoxicity recovered within 2 months.
Bacterial Coinfection Associated With Poor COVID-19 Outcomes in Chronic Lymphocytic Leukemia
Researchers sought to determine the case fatality rate in patients with CLL who were infected with SARS-CoV-2.
- Loading...
Loading...
Next post in Leukemia
Loading... 
Loading...